Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications

Author(s): Maria J. Alvarez-Cubero, Fernando Vázquez-Alonso, Ignacio Puche-Sanz, F. Gabriel Ortega, M. Martin-Prieto, José L. Garcia-Puche, Manrique Pascual-Geler, José A. Lorente, José M. Cozar-Olmo, Maria J. Serrano

Journal Name: Current Drug Targets

Volume 17 , Issue 6 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Circulating Tumor Cells (CTCs) are a valuable prognostic factor in several solid tumors. By understanding the biological characteristics of CTCs we could better understand the biology of metastasis. CTCs usually adopt a dormant state that is believed to be a strategy to survive in extreme conditions. To enter a dormant state, CTCs undergo numerous phenotypic, genetic and functional mutations that significantly affect the efficacy of the therapies used to kill dormant CTCs. Hence, understanding the biological events involved in the dormancy process of CTCs would allow the identification of new therapeutic targets. Some experimental studies or preclinical models have explored these biological events, as well as the molecular factors that contribute to the maintenance of and release from dormancy. However, few studies have assessed the effects of anticancer therapies on dormant cells. This study reviews current the data currently available on cell dormancy mechanisms in prostate cancer, with a special focus on the functional, genetic and phenotypic plasticity of CTCs and their potential implications in the clinical and therapeutic management of prostate cancer.

Keywords: CTCs, dormancy, EMT, miRNA, prostate cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 23 March, 2016
Page: [693 - 701]
Pages: 9
DOI: 10.2174/1389450116666150309121346
Price: $65

Article Metrics

PDF: 56
PRC: 1